• Net Revenue Growth: G1 Therapeutics Inc (NASDAQ:GTHX) achieved a 48% increase in net revenue from COSELA sales in 2023, amounting to $46.3 million.

• Fourth Quarter Performance: The company reported a 29% growth in net COSELA revenue in Q4 2023, reaching $13.9 million.

• Operational Efficiency: Operating expenses significantly reduced, contributing to a lower net loss compared to the previous year.

• Research and Development: R&D expenses decreased as the company focused on ongoing clinical trials, including the pivotal PRESERVE 2 trial.

• 2024 Revenue Guidance: G1 Therapeutics provided a net revenue guidance of $60 to $70 million for COSELA in 2024.

• Financial Position: The company ended 2023 with $82.2 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2025.

• Warning! GuruFocus has detected 4 Warning Signs with GTHX.

G1 Therapeutics Inc (NASDAQ:GTHX), a commercial-stage biopharmaceutical company, released its 8-K filing on February 28, 2024, detailing its financial results for the fourth quarter and full year of 2023. The company, known for developing novel therapies for cancer treatment, reported a significant increase in net revenue driven by sales of its flagship product, COSELA (trilaciclib).

For the full year 2023, G1 Therapeutics saw net revenue from COSELA sales grow by 48% to $46.3 million, with a 29% increase in the fourth quarter alone, reaching $13.9 million. This growth comes despite a platinum-based chemotherapy shortage, underscoring the drug's importance in treating extensive-stage small cell lung cancer and the potential for further market penetration.

Financial Highlights and Operational Efficiency

The company's financial discipline is evident in its reduced operating expenses, which decreased from $41.1 million in Q4 2022 to $23.8 million in Q4 2023. Full-year operating expenses also saw a significant reduction from $187.5 million in 2022 to $122.0 million in 2023. This operational efficiency contributed to a lower net loss of $10.9 million in Q4 2023, compared to $33.6 million in the same quarter of the previous year. The full-year net loss also improved, shrinking from $147.6 million in 2022 to $48.0 million in 2023.

Research and development expenses were $7.4 million for Q4 2023, a decrease from $16.6 million in Q4 2022, reflecting a strategic focus on key clinical trials. Selling, general, and administrative expenses also decreased, from $23.6 million in Q4 2022 to $15.2 million in Q4 2023, due to reduced commercialization activities and personnel costs.